NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Wednesday that its revenues for the second quarter increased 71 percent year over year, but still fell short of the consensus analysts' estimate.

It also said that it and Genzyme have agreed to amend their co-promotion agreement reached in early 2012.

The South San Francisco, Calif.-based firm said that for the three months ended June 30, revenues reached $8.7 million, compared to $5.1 million in the year-ago period. On average, Wall Street had expected revenues of $9.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.